Clarence Thomas

The Hoover Institution will premiere 'The Sowell Legacy' on July 30, a multimedia series exploring the life, work, and influence of economist and public intellectual Thomas Sowell. The six-episode series combines conversations, archival footage, photography, and animation, drawing on Hoover's 2025 Thomas Sowell Legacy Conference. It features participants including Justice Clarence Thomas, Victor Davis Hanson, Niall Ferguson, Coleman Hughes, Glenn Loury, Roland Fryer, Charles Murray, Ayaan Hirsi Ali, and others. Episodes examine Sowell's contributions to economics, race and culture, education, social policy, and intellectual freedom, covering works like 'Basic Economics' and 'A Conflict of Visions'. The series opens with a discussion on Sowell's work as a cultural historian. New installments will be released throughout summer and fall across Hoover's digital platforms.

1 reports · 1 sources · Updated Jul 29, 12:00 AM UTC

The U.S. Supreme Court agreed to hear *Jouppi v. Alaska*, where 82-year-old pilot Ken Jouppi challenges the state's seizure of his $95,000 Cessna after a passenger brought a six-pack of beer to a dry village in 2012. Jouppi, represented by the Institute for Justice, argues the forfeiture violates the Eighth Amendment's Excessive Fines Clause, as the plane's value far exceeds his $1,500 fine and three-day sentence. The case could clarify limits on civil asset forfeiture and state power.

13 reports · 5 sources · Updated Jul 22, 10:00 AM UTC

The Supreme Court's decision in Trump v. Cook, while technically narrow, has significant implications for Federal Reserve independence. The Court ruled that members of the Federal Reserve Board of Governors cannot be removed by the President for policy disagreements or at will, but only 'for cause' as specified in the Federal Reserve Act. This halted President Trump's attempt to remove Governor Lisa Cook over allegations of mortgage fraud. The Court interpreted the 'for cause' requirement to include procedural protections, making removal difficult without substantial new evidence. The 5-4 decision saw Chief Justice Roberts writing the majority opinion, joined by Justice Kavanaugh and the three liberal justices. Dissenting justices argued the Court should have limited its ruling to the injunction. The article also discusses background on the case, the nature of required removal procedures, and remaining questions about the scope of Fed independence beyond monetary policy.

1 reports · 1 sources · Updated Jul 21, 11:48 AM UTC

Legal experts and commentators are criticizing Supreme Court Justice Samuel Alito following his dissent in a recent ruling that preserved telehealth access to the abortion pill mifepristone. In a bonus episode of Slate’s "Amicus" podcast, host Mark Joseph Stern and legal scholar Madiba Dennie analyzed Alito’s reaction, describing him as visibly angry that blue states have successfully circumvented restrictions imposed after the overturning of Roe v. Wade. Dennie noted Alito’s frustration that abortion rates in states like Louisiana have increased due to telehealth access, suggesting his primary goal was ending abortion nationwide rather than restoring state sovereignty. Stern argued that Alito’s dissent reveals a selective view of federalism, where red states can restrict abortion but blue states cannot protect it. Dennie drew historical parallels to pre-Civil War era conflicts, arguing that conservative justices are attempting to impose restrictive laws across state lines. The Supreme Court issued the 7-2 emergency order to maintain access to mifepristone, rejecting attempts to ban its distribution via mail and telehealth.

1 reports · 1 sources

The U.S. Supreme Court issued a temporary order preserving widespread access to mifepristone, rejecting lower-court rulings that sought to ban mail-order distribution and impose in-person visit requirements. This 7-2 emergency decision maintains the status quo for telehealth abortions while legal challenges from Louisiana and anti-abortion groups continue. Justices Thomas and Alito dissented, arguing the ruling undermines previous abortion restrictions. The decision provides immediate relief for patients nationwide but leaves long-term access uncertain as litigation proceeds, highlighting ongoing political and legal tensions surrounding reproductive rights in the post-Roe era.

15 reports · 12 sources · Updated May 16, 10:14 AM UTC

The US Supreme Court has granted a stay on a federal appeals court decision that sought to restrict mail-order distribution of mifepristone, allowing the abortion pill to remain available by mail while litigation continues. This decision maintains access to the drug, which is used in over 60 percent of abortions, despite strong dissents from Justices Clarence Thomas and Samuel Alito, who argued the move undermines the Dobbs decision. In other news, recent diplomatic meetings between President Donald Trump and Chinese President Xi Jinping resulted in few concrete outcomes, with vague statements on bilateral relations and no progress on key issues like Taiwan or export restrictions. Domestically, New York lawmakers are considering a one percent tax on cash purchases of homes valued at over one million dollars. Additionally, the Justice Department reported findings of racial discrimination against white and Asian applicants at Yale University's medical school, part of broader probes into alleged bias in higher education institutions.

1 reports · 1 sources

The U.S. Supreme Court has issued an order on its shadow docket granting a stay of a Fifth Circuit Court of Appeals decision that sought to block FDA regulations allowing the prescription of mifepristone for abortion via telemedicine. This temporary measure preserves access to the medication while the legal appeal proceeds, with the case expected to return to the Court in the future. The majority opinion did not record individual votes, but Justices Clarence Thomas and Samuel Alito filed dissenting opinions. They argued that the manufacturers failed to demonstrate irreparable harm, noting that federal law (the Comstock Act) technically prohibits mailing abortifacients and that the FDA did not intervene to defend the regulation. The dissenters suggested that any financial loss claimed by manufacturers stemmed from potentially illegal activities. The article highlights the unusual absence of federal government support for the FDA rule in this litigation, contrasting it with the strong legal standing of the pharmaceutical manufacturers who successfully argued that the lower court's reasoning was flawed and based on vacated precedents.

1 reports · 1 sources

This news digest covers several significant global and domestic developments. The US Supreme Court temporarily blocked a lower court ruling, preserving access to mail-order abortion pills (mifepristone) in a 7-2 decision, though the legal battle continues. In global health news, the Africa CDC declared an Ebola outbreak in the Democratic Republic of Congo's Ituri province, citing 246 suspected cases and 65 deaths, with concerns about urban spread and regional instability. Politically, a new study links President Trump's dismantling of USAID to increased violent conflict in regions previously receiving US aid, showing a 6.5% higher probability of conflict. Domestically, the Department of Justice accused Yale and UCLA medical schools of discriminating against non-Black and non-Hispanic applicants, challenging their diversity initiatives. Additionally, MIT reported a 10% shrinkage in its research enterprise due to federal funding shortfalls and policy changes under the Trump administration. These stories highlight ongoing tensions in healthcare access, international aid efficacy, and higher education policy in the United States.

1 reports · 1 sources

The United States Supreme Court has temporarily maintained mail-order access to mifepristone, a widely used abortion medication, pending a final decision on the merits of the case. This ruling extends a suspension of a May 1 decision by a conservative appeals court that had sought to block postal distribution of the drug. The emergency appeal was filed by manufacturers Danco Laboratories and GenBioPro, who warned that restricting teleprescribing and mailing would cause immediate confusion and disrupt sensitive medical timelines for patients nationwide. While the decision provides temporary relief, reproductive rights advocates express concern that access remains threatened by ongoing legal challenges and a politically motivated safety review initiated by the Trump administration and the FDA. Conservative justices Samuel Alito and Clarence Thomas dissented from the order. Anti-abortion groups, including Pro-Life America, voiced deep disappointment with the outcome. Mifepristone is involved in nearly two-thirds of abortions in the US, where federal protections were removed in 2022, leaving regulation to individual states, many of which have enacted strict bans or limitations.

1 reports · 1 sources

The US Supreme Court has issued an order preserving women's access to mifepristone, the drug used in the most common method of abortion, while legal challenges continue. The decision rejects lower-court restrictions that would have required in-person doctor visits and halted mail delivery of the medication. This emergency relief allows patients to obtain the drug through pharmacies or via mail without immediate disruption, likely maintaining the status quo until at least next year as the case proceeds through appeals. The ruling grants requests from manufacturers Danco Laboratories and GenBioPro, overturning a Fifth Circuit Court of Appeals decision that favored Louisiana’s lawsuit against FDA regulations. Justices Clarence Thomas and Samuel Alito dissented, arguing the manufacturers are not entitled to protect profits from what they termed illegal activities under the Comstock Act. The case highlights ongoing tensions between anti-abortion groups and the FDA regarding telehealth prescriptions and safety reviews. With medication abortions accounting for nearly two-thirds of all procedures in 2023, this decision significantly impacts reproductive healthcare access across the United States, particularly in states with strict abortion bans.

1 reports · 1 sources

The U.S. Supreme Court has issued an emergency stay allowing continued access to medication abortion via telemedicine and mail, effectively blocking a recent ruling by the 5th U.S. Circuit Court of Appeals. The appellate court had previously mandated in-person dispensing of mifepristone, citing conflicts with Louisiana’s abortion ban. This Supreme Court decision maintains the status quo pending further appeals, preserving a Biden-era pandemic policy that significantly expanded access to reproductive healthcare. Justices Clarence Thomas and Samuel Alito Jr. dissented from the order. The case involves pharmaceutical manufacturers Danco Laboratories LLC and GenBioPro Inc., who argued that restricting mail distribution would create regulatory chaos contradicting FDA policies. Mifepristone has been available in the U.S. for 25 years, with medication abortions accounting for 63 percent of all procedures in 2023. The ruling occurs amidst political tension, following the resignation of FDA Commissioner Marty Makary and a renewed Senate Democratic resolution affirming the drug's safety. This development is critical for patients in Republican-led states where access to abortion services is increasingly restricted.

1 reports · 1 sources

The US Supreme Court has issued an emergency order allowing the continued prescription and mail-order shipment of abortion pills, specifically mifepristone, across the United States. This decision stays a lower appeals court ruling that had blocked a 2023 Food and Drug Administration (FDA) regulation facilitating telemedicine access to the drug. The high court approved urgent applications from pharmaceutical manufacturers Danco Laboratories and GenBioPro, with conservative Justices Samuel Alito and Clarence Thomas dissenting. The legal challenge was initiated by Louisiana, which argued the FDA rule ignored health risks, but the Trump administration opposed the state's lawsuit, citing lack of standing and ongoing safety reviews. This ruling is significant as abortion rights remain a central issue ahead of the November congressional elections. Since the Supreme Court overturned the nationwide right to abortion in 2022, medical abortions have risen to account for approximately two-thirds of all procedures in the country. The FDA and experts continue to classify mifepristone, approved since 2000, as safe and effective.

1 reports · 1 sources

During Donald Trump's second presidency, CIA Director John Ratcliffe held meetings with senior Cuban government officials in Havana. The Cuban government stated the visit aimed to promote political dialogue and demonstrate that Cuba poses no threat to US national security, arguing against its inclusion on the US state sponsors of terrorism list. President Trump had reinstated this designation in January 2025. Concurrently, prominent Cuban dissident Sissi Abascal Zamora was released from prison and exiled to the United States. In domestic US news, the Supreme Court issued an emergency order staying a lower court decision that would have restricted access to the abortion medication mifepristone. The Trump administration opposed the lawsuit brought by Louisiana, asserting the state lacked standing. This legal development highlights the ongoing tension surrounding abortion rights following the 2022 overturning of Roe v. Wade, with the issue expected to influence the upcoming November congressional elections. The FDA maintains that mifepristone is safe and effective, while conservative justices Alito and Thomas dissented from the unsigned order.

1 reports · 1 sources

The U.S. Supreme Court has issued an order preserving women's access to mifepristone, the primary drug used in medication abortions, while a legal challenge proceeds. The decision rejects lower-court restrictions that would have mandated in-person doctor visits and halted mail-order distribution of the drug. This emergency relief allows patients to continue obtaining mifepristone through pharmacies and telehealth services without interruption, likely until at least next year. The ruling grants requests from manufacturers Danco Laboratories and GenBioPro, who are appealing a federal appeals court decision favoring Louisiana’s attempt to roll back FDA regulations. Justices Clarence Thomas and Samuel Alito dissented, arguing the manufacturers profit from illegal activities under state laws and the Comstock Act. The case highlights ongoing tensions between anti-abortion groups and the FDA regarding drug safety and access protocols. While abortion-rights advocates expressed relief, they emphasized that healthcare access should not depend on judicial outcomes. Conversely, anti-abortion groups view the decision as disappointing but maintain hope for a full hearing. This development occurs four years after the overturning of Roe v. Wade, continuing the national debate over reproductive rights.

1 reports · 1 sources

The US Supreme Court has issued a temporary stay on a federal appeals court ruling that sought to ban telemedicine and mail-order prescriptions for the abortion pill mifepristone. This one-paragraph order, released late Thursday, ensures that mifepristone remains accessible via telehealth and mail for the foreseeable future, even in states with strict abortion bans. The decision halts the Fifth Circuit Court of Appeals' earlier attempt to suspend FDA rules established during the Biden administration, which had removed in-person dispensing requirements. The case has generated significant legal and political tension since the overturning of Roe v. Wade. While Justices Samuel Alito and Clarence Thomas dissented, arguing the move undermines state laws and citing the Comstock Act, the majority chose to maintain current access levels. This ruling provides temporary relief to abortion providers and patients amidst ongoing nationwide legal battles over reproductive rights. It highlights the continuing conflict between federal regulatory authority and state-level restrictions following the Dobbs decision, affecting millions of Americans who rely on medication abortions.

1 reports · 1 sources

The US Supreme Court has issued an emergency order restoring access to the abortion pill mifepristone via mail, temporarily blocking restrictions imposed by a lower court. This ruling allows the medication to remain available through telemedicine and postal delivery while ongoing litigation proceeds, a process that could extend into next year. The decision follows a lawsuit filed by the state of Louisiana against the Food and Drug Administration (FDA), which had permanently authorized mail-order distribution in 2023. Louisiana argued that nationwide postage of the drug undermined its state-level abortion ban. Two manufacturers of mifepristone petitioned the Supreme Court to intervene after an appeals court reinstated in-person dispensing requirements. The Supreme Court's stay was issued without detailed reasoning. Justices Clarence Thomas and Samuel Alito dissented, with Justice Thomas characterizing the mail distribution as illegal in Louisiana and dismissing the manufacturers' claims based on lost profits from what he termed a criminal enterprise. Mifepristone remains the most common method for terminating pregnancies in the United States, particularly in states where surgical abortion is banned or heavily restricted following the overturning of Roe v. Wade.

1 reports · 1 sources

The US Supreme Court has issued an order extending a stay that temporarily preserves nationwide mail access to mifepristone, a widely used abortion medication. This decision halts the enforcement of a previous ruling by the US 5th Circuit Court of Appeals, which had sought to ban the mailing of the drug and require in-person pickups at health clinics. The legal challenge originated from a lawsuit filed by the state of Louisiana against the Food and Drug Administration (FDA), arguing for stricter regulations on the drug's distribution. Manufacturers Danco Laboratories and GenBioPro successfully petitioned the Supreme Court to pause the appeals court's order while they prepare for further legal proceedings. Justices Samuel Alito and Clarence Thomas dissented from the majority decision to extend the stay. Mifepristone, approved by the FDA since 2000, is utilized in the majority of abortions in the United States and for managing early miscarriages. This ruling maintains the status quo regarding telemedicine prescriptions and mail-order delivery until the Supreme Court decides whether to hear the case fully, amidst ongoing national debates and varying state-level restrictions on abortion access following the overturning of Roe v. Wade.

1 reports · 1 sources

The US Supreme Court issued a 7-2 decision to maintain access to the abortion medication Mifepristone via mail and telehealth, extending a previous stay on a lower court ruling that sought to restrict such distribution. This interim measure is not a final verdict; the case will return to the New Orleans-based appeals court and may eventually revisit the Supreme Court. Conservative Justices Samuel Alito and Clarence Thomas authored scathing dissenting opinions. Justice Alito argued that the current access scheme undermines the Court's earlier Dobbs v. Jackson decision, which overturned Roe v. Wade. He accused drug manufacturers of profiting from the felonious use of the drug in Louisiana, claiming that more abortions now occur there than before the Dobbs ruling due to out-of-state providers. Justice Thomas similarly criticized the manufacturers, labeling their operations a criminal enterprise and arguing they are not entitled to relief based on lost profits. The decision highlights the ongoing legal and ideological battles surrounding reproductive rights in the United States following the reversal of federal constitutional protections for abortion.

1 reports · 1 sources

The US Supreme Court has issued an emergency order indefinitely blocking a lower court ruling that sought to restrict access to mifepristone, a commonly used abortion medication. This decision in Danco Laboratories v. Louisiana ensures the drug remains accessible while the case undergoes full litigation, likely keeping it available until at least June 2027. The order prevents the Fifth Circuit Court of Appeals from enforcing restrictions on the drug's distribution, particularly via mail. While the Court did not disclose individual votes, Justices Clarence Thomas and Samuel Alito publicly dissented. Thomas characterized the pharmaceutical manufacturers as a criminal enterprise under the Comstock Act, while Alito alleged an unlawful conspiracy. This marks the second time the Supreme Court has intervened to protect mifepristone access, following a 2024 ruling that dismissed a similar challenge on jurisdictional grounds. The decision provides temporary relief for abortion providers and patients amid ongoing legal battles over reproductive rights in the United States.

1 reports · 1 sources

The U.S. Supreme Court has issued an order preserving access to mifepristone, a key medication used in abortions, while legal challenges continue. The decision rejects lower-court restrictions that would have required in-person doctor visits and halted mail-order distribution of the drug. This ruling ensures that women can continue obtaining mifepristone through pharmacies and telehealth services without interruption, at least until the case proceeds further, potentially into next year. The emergency stay was granted in favor of the drug's manufacturers, Danco Laboratories and GenBioPro, who appealed a federal appeals court decision. Justices Clarence Thomas and Samuel Alito dissented, arguing against the manufacturers' actions. The lawsuit, initiated by Louisiana, challenges FDA regulations approved in 2000 and modified five years ago to allow remote prescribing. Anti-abortion groups are pressuring the Trump administration to expedite reviews aimed at restricting access, citing safety concerns despite FDA affirmations of the drug's efficacy. This development occurs four years after the overturning of Roe v. Wade, highlighting ongoing national debates over reproductive rights and federal regulatory authority.

1 reports · 1 sources

The US Supreme Court has issued an order preserving nationwide access to mifepristone, a widely used abortion medication, while legal challenges proceed. The decision rejects lower-court restrictions that would have halted mail delivery and required in-person doctor visits, effectively maintaining the status quo established by the FDA five years ago. This emergency stay grants relief to manufacturers Danco Laboratories and GenBioPro, ensuring uninterrupted access via pharmacies and mail at least until next year. Justices Clarence Thomas and Samuel Alito dissented, arguing that the companies profit from what they termed a criminal enterprise violating the Comstock Act and state laws. The case originates from a lawsuit by Louisiana, which contends that federal prescribing rules undermine its state abortion ban and question drug safety, despite FDA affirmations. The ruling occurs within a charged political environment under President Donald Trump’s administration, where anti-abortion groups are pressuring the FDA for stricter regulations. This development follows the recent resignation of FDA Commissioner Marty Makary amid criticism from Trump allies. The court's action highlights the continuing legal and political friction surrounding abortion access four years after the overturning of Roe v. Wade.

1 reports · 1 sources

The United States Supreme Court has issued a significant ruling allowing women to continue accessing the abortion medication Mifepristone through telehealth consultations. This decision effectively blocks a lower court ruling from the Fifth Circuit Court of Appeals, which had abruptly mandated that patients obtain the drug through in-person visits. By maintaining the stay on the Fifth Circuit's May 1 decision, the Supreme Court preserves the current status quo while ongoing litigation proceeds. Although the conservative-led court did not provide a detailed explanation for its reasoning or disclose the full vote count, it was reported that Justices Clarence Thomas and Samuel Alito dissented from the majority opinion. The legal battle now shifts back to the New Orleans-based appeals court, which will be responsible for deciding the merits of the challenge brought by officials in Louisiana. These state officials are continuing their efforts to limit the availability of Mifepristone. This temporary victory for abortion rights advocates ensures that remote access to the medication remains available during the judicial review process, highlighting the continued contentious nature of reproductive health legislation in the United States.

1 reports · 1 sources

The U.S. Supreme Court has ruled to allow the mail-order distribution of the abortion medication mifepristone while an appeal challenging this method proceeds. This decision effectively maintains a temporary stay on a nationwide ban issued by the 5th Circuit U.S. Court of Appeals on May 1, which had prohibited mailing the drug. The legal battle originated when Louisiana, a state with strict abortion bans, sued the Food and Drug Administration (FDA) over its 2023 decision to remove the in-person dispensing requirement for mifepristone. Although the Supreme Court did not disclose the vote count or provide a majority explanation, conservative Justices Clarence Thomas and Samuel Alito issued written dissents against extending the stay. Pharmaceutical manufacturers Danco Laboratories and GenBioPro had petitioned the high court to lift the lower court's ban. This ruling marks a significant development in the ongoing legal conflicts surrounding reproductive rights and FDA regulatory authority following the overturning of federal constitutional protections for abortion. The decision ensures continued access to mail-order mifepristone across the United States until the appellate process concludes.

1 reports · 1 sources

The U.S. Supreme Court issued an unsigned order on Thursday, May 14, 2026, maintaining the current availability of mifepristone, a key medication used for abortions. This decision blocks a ruling by the 5th Circuit Court of Appeals that sought to reimpose strict in-person dispensing requirements and ban the mailing of the drug. Justices Samuel Alito and Clarence Thomas filed separate dissents against the majority's decision. Justice Thomas argued based on the Comstock Act, characterizing the distribution of the drug as a criminal enterprise and stating that manufacturers could not claim irreparable harm from restrictions on illegal activities. Justice Alito criticized the stay as undermining the Court's previous Dobbs decision, expressing strong opposition to the drug manufacturers, Danco and GenBioPro. He dismissed their claims of operational inconvenience and lost sales as insufficient evidence of irreparable injury. While this order provides a temporary reprieve for access to mifepristone, the case is expected to return to the Supreme Court for a review on its merits. With a conservative majority, the future availability of the drug remains uncertain as legal battles continue following the overturning of federal abortion protections.

1 reports · 1 sources

The U.S. Supreme Court has issued a 7-2 decision upholding federal regulations that allow the mailing of mifepristone, an FDA-approved medication used for early pregnancy termination. The ruling rejects an emergency challenge brought by anti-abortion advocates and sets aside a previous order from the 5th Circuit Court of Appeals that sought to ban the distribution of these pills via mail. Justices Clarence Thomas and Samuel Alito Jr. dissented, with Justice Alito arguing that the decision undermines the Dobbs v. Jackson Women’s Health Organization precedent, which returned abortion regulation authority to individual states. This legal victory is considered a significant setback for opponents who claim the medication is unsafe, despite the FDA’s long-standing approval and recent regulatory relaxations initiated during the pandemic. The case will now return to the lower courts for further review while the FDA continues its own assessment of the drug's safety protocols. Medication abortions currently account for nearly two-thirds of all abortions in the United States, making access to telehealth services and mail-order prescriptions a critical component of reproductive healthcare availability nationwide.

1 reports · 1 sources

The US Supreme Court has issued an order preserving nationwide access to the abortion drug mifepristone via mail and telehealth, effectively blocking a recent ruling by the Fifth Circuit Court of Appeals. The lower court had reinstated an in-person requirement for obtaining the medication, a decision that advocates warned would severely restrict access for millions of patients, particularly in states where abortion is banned. By freezing the lower court's ruling, the Supreme Court ensures that the Food and Drug Administration’s 2021 decision allowing remote prescriptions remains in effect while the legal battle continues. Justices Clarence Thomas and Samuel Alito filed dissenting opinions, with Alito citing the Comstock Act, an 1873 law prohibiting the mailing of substances intended for abortion. This development marks a significant continuation of high-profile legal conflicts over reproductive rights following the overturning of Roe v. Wade. Medication abortions currently account for approximately 63 percent of all abortions in the United States, making access to mifepristone critical for reproductive healthcare provision across the country.

1 reports · 1 sources

The U.S. Supreme Court has issued an unsigned order maintaining nationwide mail access to the abortion medication mifepristone, temporarily setting aside a lower court ruling that sought to reinstate in-person dispensing requirements. This decision ensures that patients can continue to obtain the drug via telehealth and mail while litigation challenging the Food and Drug Administration's relaxed policies proceeds. The case was initiated by Louisiana, which argued that remote access allows out-of-state providers to evade its strict abortion bans, resulting in thousands of unlawful procedures within the state. Conservative Justices Samuel Alito and Clarence Thomas dissented from the majority's decision. Pharmaceutical manufacturers Danco Laboratories and GenBioPro had urged the Court to block the appellate ruling, citing confusion and disruption to healthcare services. The FDA, which formally allowed mail-order prescriptions in 2023 following pandemic-era adjustments, did not take a position in this specific appeal. This ruling preserves broad access to mifepristone, which is used in a significant majority of clinician-provided abortions in the United States, amidst ongoing legal and political debates following the overturning of Roe v. Wade.

1 reports · 1 sources

The U.S. Supreme Court has ruled that the abortion pill mifepristone can continue to be distributed by mail across the nation without requiring an in-person consultation with a clinician. This decision grants emergency requests filed by drug manufacturers Danco Laboratories and GenBioPro, effectively blocking a recent ruling by the 5th U.S. Circuit Court of Appeals that had threatened to restrict access to the medication. The 5th Circuit's May 1 decision, which favored the state of Louisiana, argued against the current distribution methods. However, the Supreme Court's intervention ensures no disruption to the drug's availability while legal proceedings continue. Justices Clarence Thomas and Samuel Alito issued dissenting opinions. Justice Thomas characterized the mailing of mifepristone as illegal in Louisiana and criticized the manufacturers, while Justice Alito questioned the Biden administration's 2023 decision to allow mail-order access. Mifepristone, used in conjunction with another drug, represents the most common method of abortion in the United States. This ruling marks a significant development in the ongoing legal battles surrounding reproductive rights and FDA regulations post-Roe v. Wade.

1 reports · 1 sources

This analysis challenges the perception of the Roberts Court as uniformly pro-corporate, highlighting a emerging trend against broad federal preemption. While corporations typically favor preemption to avoid state liability, conservative justices like Clarence Thomas and Neil Gorsuch often oppose it on federalist grounds. The article examines three recent cases: Hencely v. Fluor Corp, where the Court ruled federal law did not preempt state tort claims; Montgomery v. Caribe Transport II, LLC, a unanimous decision rejecting preemption for transportation brokers; and the pending Monsanto Company v. Durnell case. In these instances, the Court prioritizes statutory text over corporate interests, with Justice Barrett emphasizing that legislative fixes belong to Congress, not the judiciary. Consequently, forming a five-justice majority for preemption has become difficult, creating an 'Antipreemption Court' dynamic. This shift suggests that even conservative justices are unwilling to engage in creative statutory interpretations to shield corporations from state suits, marking a significant jurisprudential development that complicates traditional ideological alignments within the Supreme Court.

1 reports · 1 sources

Following the Supreme Court's decision to overturn his IEEPA tariffs, Donald Trump has expressed dissatisfaction with justices he appointed, sparking speculation about potential new nominations. This reaction highlights a significant radicalization within the conservative legal movement. Despite securing a right-wing supermajority that achieved major goals like overturning Roe v. Wade and limiting the administrative state, hardline conservatives now distrust established figures like Justice Amy Coney Barrett. The traditional refrain of "no more Souters" has evolved into "no more Robertses. No more Barretts," reflecting demands for absolute ideological loyalty. Internal skirmishes are emerging over who qualifies as a true heir to Justices Alito and Thomas. Even extreme lower-court judges like Fifth Circuit Judge Andrew Oldham, known for aggressive culture-war rhetoric, face criticism from some commentators who view them as insufficiently committed. This shift indicates that the conservative legal movement is imposing stricter purity tests on prospective nominees, prioritizing unwavering allegiance to Trump's agenda over traditional conservative judicial credentials. The article analyzes this internal political dynamic and the changing criteria for judicial selection within the Republican party.

1 reports · 1 sources